BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) has granted restricted stock units (RSUs) to seven newly-hired employees, covering a total of 48,000 shares of common stock. The RSUs were awarded on May 1, 2025 as employment inducements and comply with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years in equal annual installments, beginning one year from the grant date, contingent on continued employment. These grants are governed by BioCryst's Inducement Equity Incentive Plan and individual RSU agreements.

RESEARCH TRIANGLE PARK, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 48,000 shares of BioCryst common stock. The RSUs were granted as of May 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

FAQ

What is the vesting schedule for BCRX's May 2025 RSU grants?

The RSUs vest in four equal annual installments, with the first vesting occurring on the one-year anniversary of the May 1, 2025 grant date, subject to continued employment.

How many shares of BCRX stock were granted as RSUs in May 2025?

BioCryst granted RSUs covering 48,000 shares of common stock to seven newly-hired employees.

What is the purpose of BCRX's RSU grants announced in May 2025?

The RSUs were granted as inducements material to each employee entering into employment with BioCryst, in accordance with Nasdaq Listing Rule 5635(c)(4).

Under which plan were BCRX's May 2025 RSU grants issued?

The RSUs were issued under BioCryst's Inducement Equity Incentive Plan and are subject to individual restricted stock unit agreements.